Ms. Glaub brings more than 30 years of experience in corporate development and strategy, financing and company-building for innovative life science and technology companies. She became a co-founder of CuraSen in 2018. Ms. Glaub also serves on the board of directors of Escient Pharmaceuticals, IO Biotech and Codexis, Inc.
Following Ms. Glaub’s appointment to the board of Afferent Pharmaceuticals in 2013, she joined the company as chief executive officer in 2014. Ms. Glaub led the company’s advancement of AF-219/MK7264 (gefapixant) to Phase 3 readiness for the treatment of chronic cough, raised $80 million in additional private funding for Afferent, and led the 2016 sale of the company to Merck for $1.25 billion.
Previously, Ms. Glaub served as president of Plexxikon for 12 years, where she led the company’s business and financing strategies, negotiated several multi-million-dollar partnerships, and led the sale of the company to Daiichi Sankyo for nearly $1 billion in 2011. She also was instrumental in Plexxikon’s advancement of multiple novel molecules to the clinic, as well as advancement of Zelboraf®, a targeted treatment for melanoma, along with its companion diagnostic to market approval in 2011. She previously held positions as senior vice president and chief financial officer of Cell Genesys, treasurer of Genentech, and various finance and treasury roles with Intel Corporation.
Ms. Glaub received her BA from the University of California, Berkeley, and her MBA from Northwestern University.